Seres expects its experimental C. difficile therapy to launch in the first half of 2023 if it's approved by FDAMarket Watch • 06/07/22
Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile InfectionBusiness Wire • 06/07/22
Seres Therapeutics Presents Microbiome Therapeutic Research at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingBusiness Wire • 06/01/22
Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual MeetingBusiness Wire • 05/22/22
Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual MeetingBusiness Wire • 05/10/22
Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/04/22
Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business UpdatesBusiness Wire • 05/04/22
Seres Therapeutics to Host First Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2022Business Wire • 04/28/22
Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual MeetingBusiness Wire • 03/18/22
Seres Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare ConferenceBusiness Wire • 03/10/22
Seres Therapeutics to Participate in Cowen 42nd Annual Health Care ConferenceBusiness Wire • 03/03/22
Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/01/22
Seres Therapeutics (MCRB) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/01/22
Seres Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdatesBusiness Wire • 03/01/22
Seres Therapeutics to Present at Chardan Metagenomics and Microbiome Medicines SummitBusiness Wire • 02/22/22
Seres Therapeutics to Host Fourth Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on March 1, 2022Business Wire • 02/22/22
Seres Therapeutics Appoints Paula Cloghessy as Executive Vice President, Chief People OfficerBusiness Wire • 02/08/22
Seres Therapeutics to Host Virtual Investor Event Highlighting Opportunities for Microbiome Therapeutics in Infection Protection on January 31, 2022Business Wire • 01/24/22
Seres Therapeutics' Oral Microbiome Candidate Shows Meaningful Improvements In Difficile InfectionBenzinga • 01/20/22
New England Journal of Medicine Publishes Data from ECOSPOR lll Phase 3 Study Evaluating Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile InfectionBusiness Wire • 01/19/22
Seres Therapeutics to Present at 40th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/04/22
Seres Announces Preliminary SER-287 Phase 2b ECO-RESET Study Microbiome Data AnalysisBusiness Wire • 12/16/21
Will The Rally Continue In Seres Therapeutics (MCRB) Stock After A Stellar 77% Surge In A Month?Forbes • 12/02/21